Overall, the increased upregulation of CXCL9 and CXCL10, accompanied with the downregulation in CXCL2, may underlie the observed alterations in the cellular components at the level of systemic organs and within the tumor microenvironment following combination treatment. Here, CXCL10 is linked to neoplasm.